The document discusses planning and reporting of stability studies for pharmaceutical products. It provides definitions of key terms from ICH guidelines related to stability testing of active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs). Specifically, it defines terms like re-test date, shelf life, formal stability studies, stress testing, primary and commitment batches, and more. It also discusses requirements for stability protocols and reports, including details of batches tested, storage conditions, analytical methods used, and results. Forced degradation studies aim to identify potential degradation pathways and validate stability-indicating methods.
stability tests for pharmaceutical productsalaaalfayez
These documents provide guidance on stability testing and evaluation for pharmaceutical products. The purpose of stability testing is to provide evidence on how a drug product's quality varies over time under various environmental conditions. Key aspects addressed include testing the drug substance and finished product under different timepoints and storage conditions to establish or extend a product's shelf life. The documents outline best practices for conducting long-term, accelerated, and intermediate stability studies to evaluate the impact of factors like temperature, humidity, and light on a product's physical, chemical, biological, and microbiological properties over time.
Stability protocols for different dosage forms by sachin jainManish Kumar
This document discusses stability protocols for different dosage forms. It provides an overview of stability testing and definitions. It describes stability testing protocols for APIs and discusses the factors considered for different dosage forms like tablets, capsules, solutions, suspensions and more. Testing timepoints and storage conditions are outlined. The document emphasizes the importance of formal stability studies in establishing a retest date or product shelf life.
This document discusses guidelines for stability testing of pharmaceuticals according to the International Conference on Harmonization (ICH). It describes the ICH guidelines for stability testing, including stability protocols, reports, and studies. The key points covered include stability testing procedures, factors affecting drug stability, types of stability studies, and organizations that regulate stability guidelines such as the ICH.
The document discusses the Quality Target Product Profile (QTPP), which describes the quality characteristics of a drug product. The QTPP is established early in development based on factors like intended use, dosage form, and safety/efficacy requirements. It serves as the basis for product design and helps justify choices around dosage, packaging, and delivery. The QTPP should be updated as development progresses and knowledge about the product evolves. Key components of a QTPP include details on the active substance, finished product specifications, and packaging documentation.
Drug stability refers to a drug substance or product remaining within established specifications over time. The stability of a product is expressed as its shelf life or expiry period. Stability testing involves multiple stages from early stress testing to ongoing long-term testing as required by regulatory bodies. Stability is affected by various factors related to the drug, formulation, and environment. Reduced stability study designs like bracketing and matrixing allow testing of representative samples and are acceptable with proper scientific justification.
The document discusses the objectives and guidelines of the International Council for Harmonization (ICH) for stability testing of pharmaceutical products. It provides an overview of the key ICH guidelines for stability testing (Q1A-Q1F) and describes the principles of stability testing including establishing re-test periods and shelf lives. It also discusses the different types of stability testing, protocols, study designs like bracketing and matrixing, and key parameters for evaluation.
This document discusses stability studies and testing. Stability studies are conducted to provide evidence on how the quality of a drug substance or product varies over time under the influence of environmental factors like temperature, humidity, and light. They are required to recommend storage conditions, establish retest and shelf life periods, review product quality, and meet regulatory requirements. Key aspects covered include guidelines for stability testing, types of studies (long term, intermediate, accelerated), storage conditions, specifications, testing frequency, and requirements for stability protocols, batches, and reports.
stability tests for pharmaceutical productsalaaalfayez
These documents provide guidance on stability testing and evaluation for pharmaceutical products. The purpose of stability testing is to provide evidence on how a drug product's quality varies over time under various environmental conditions. Key aspects addressed include testing the drug substance and finished product under different timepoints and storage conditions to establish or extend a product's shelf life. The documents outline best practices for conducting long-term, accelerated, and intermediate stability studies to evaluate the impact of factors like temperature, humidity, and light on a product's physical, chemical, biological, and microbiological properties over time.
Stability protocols for different dosage forms by sachin jainManish Kumar
This document discusses stability protocols for different dosage forms. It provides an overview of stability testing and definitions. It describes stability testing protocols for APIs and discusses the factors considered for different dosage forms like tablets, capsules, solutions, suspensions and more. Testing timepoints and storage conditions are outlined. The document emphasizes the importance of formal stability studies in establishing a retest date or product shelf life.
This document discusses guidelines for stability testing of pharmaceuticals according to the International Conference on Harmonization (ICH). It describes the ICH guidelines for stability testing, including stability protocols, reports, and studies. The key points covered include stability testing procedures, factors affecting drug stability, types of stability studies, and organizations that regulate stability guidelines such as the ICH.
The document discusses the Quality Target Product Profile (QTPP), which describes the quality characteristics of a drug product. The QTPP is established early in development based on factors like intended use, dosage form, and safety/efficacy requirements. It serves as the basis for product design and helps justify choices around dosage, packaging, and delivery. The QTPP should be updated as development progresses and knowledge about the product evolves. Key components of a QTPP include details on the active substance, finished product specifications, and packaging documentation.
Drug stability refers to a drug substance or product remaining within established specifications over time. The stability of a product is expressed as its shelf life or expiry period. Stability testing involves multiple stages from early stress testing to ongoing long-term testing as required by regulatory bodies. Stability is affected by various factors related to the drug, formulation, and environment. Reduced stability study designs like bracketing and matrixing allow testing of representative samples and are acceptable with proper scientific justification.
The document discusses the objectives and guidelines of the International Council for Harmonization (ICH) for stability testing of pharmaceutical products. It provides an overview of the key ICH guidelines for stability testing (Q1A-Q1F) and describes the principles of stability testing including establishing re-test periods and shelf lives. It also discusses the different types of stability testing, protocols, study designs like bracketing and matrixing, and key parameters for evaluation.
This document discusses stability studies and testing. Stability studies are conducted to provide evidence on how the quality of a drug substance or product varies over time under the influence of environmental factors like temperature, humidity, and light. They are required to recommend storage conditions, establish retest and shelf life periods, review product quality, and meet regulatory requirements. Key aspects covered include guidelines for stability testing, types of studies (long term, intermediate, accelerated), storage conditions, specifications, testing frequency, and requirements for stability protocols, batches, and reports.
Stability study of Pharmaceutical Products and Regulatory Requirements Md. Zakaria Faruki
A marketed product stability program fulfills registration
commitments and ensures that marketed product is
stable until expiry date stamped on product
label....
Stability studies should be planned on the
basis of pharmaceutical R&D and regulatory
requirements...
The document describes the five modules of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Common Technical Document (CTD) format for ASEAN countries. Module 1 contains regional administrative information. Module 2 provides an overall summary of Modules 3, 4, and 5, including quality, non-clinical, and clinical overviews. Module 3 includes chemistry, manufacturing, and quality control documents. Module 4 contains non-clinical safety data. Module 5 provides clinical study reports, though generics only need to include bioequivalence studies. The CTD format is required for both new drug and generic applications in ASEAN countries.
This document discusses guidelines from the International Council for Harmonisation (ICH) for stability testing of drug substances and products. It provides guidance on topics such as the need for harmonized stability testing, types of stability testing, selection of batches and storage conditions for testing, and evaluation of stability data. The guidelines aim to establish a systematic approach to stability testing to ensure quality, safety and efficacy over a product's shelf life and recommend conditions for testing drug substances intended for various storage conditions.
This guideline is a revised of the ICHQ1A –stability data package for new drug substance /DRUG PRODUCT .The [urpose of guideline to define stability data package that sufficient for a registration application within the 3 regions of EU ,JAPAN & USA & to maintain the quality of drug products, in relation to safety , efficacy & acceptability throughout the propose shelf life.
The document discusses ICH stability testing guidelines for drug substances and products, outlining the types of studies required including long term, intermediate, and accelerated studies under various storage conditions. Key aspects that are evaluated include physical, chemical, and microbial changes that may occur over time and factors that influence stability such as temperature, humidity, and light exposure. The purpose of stability testing is to establish a product's shelf life and ensure it remains safe and effective when stored as recommended.
This document discusses drug stability and stability testing. It defines stability as the extent to which a product retains its properties over time. Stability testing is necessary to determine shelf life, recommended storage conditions, and ensure safety. There are various types of stability including chemical, physical, and microbiological. Testing is conducted for different formulations like tablets, capsules, emulsions, and involves evaluating attributes like appearance, assay, degradation products, and more. Guidelines provided by ICH help harmonize stability testing globally.
This document provides an overview of Six Sigma, including:
1) A brief history of Six Sigma and how it was developed at Motorola in 1987 to reduce defects by reducing process variation.
2) The two main Six Sigma project methodologies - DMAIC for improving existing processes and DMADV for creating new designs - which both follow five phases inspired by the PDCA cycle.
3) Key Six Sigma concepts like the 1.5 sigma shift, which accounts for long-term increases in process variation, and how this allows Six Sigma to be defined as a process with 3.4 defects per million opportunities.
This document provides an overview of the ICH Q1A(R2) guideline for stability testing of new drug substances and products. The guideline defines the stability data package required for drug registration in major regions. It addresses testing timelines and conditions for long term, intermediate, and accelerated studies on at least three batches of drug substance and product. The goal is to establish a re-test period or shelf life and recommended storage conditions. Specifications must cover attributes susceptible to change that could impact quality, safety or efficacy. The guideline provides detailed recommendations for testing frequency, storage conditions, and evaluation of results.
This document summarizes the ICH guideline for stability testing. The ICH provides guidance on stability testing to ensure drug quality over time under various environmental conditions. Key aspects covered include the objectives of stability testing, variables that affect stability, terminology, and ICH guidelines Q1A through Q1F which provide detailed recommendations on stability testing procedures, data evaluation, and submissions for registration.
This document defines stability testing requirements for new drug products. It outlines that three primary batches packaged in the proposed marketing container closure system should undergo long term testing at 25°C/60% RH or 30°C/65% RH, accelerated testing at 40°C/75% RH, and intermediate testing if needed. Specifications, frequency of testing, storage conditions and a post-approval stability commitment are also addressed. The purpose is to provide evidence of a drug product's quality over time under various environmental conditions and establish a shelf life.
This document discusses 21 CFR Parts 210 and 211, which outline current good manufacturing practices (cGMP) for pharmaceutical manufacturing as established by the U.S. Food and Drug Administration. It provides an overview of the various parts and subparts that comprise the cGMP regulations. These include general provisions, organization and personnel requirements, facilities and equipment specifications, production and process controls, packaging and labeling controls, and quality control. Definitions for key terms covered in the regulations are also presented, such as drug product, active pharmaceutical ingredient, batch, lot number, and theoretical and actual yields.
The document discusses Chemistry, Manufacturing and Controls (CMC) and its role in pharmaceutical product development and regulatory approval. It provides details on:
- The key functions of CMC including process development, facility inspections, and ensuring compliance.
- CMC content requirements for different application types like NDAs, ANDAs, and INDs.
- How the CMC section evolves over clinical trial phases from laboratory to commercial scale.
- Procedures for developing and submitting post-approval study protocols to regulatory agencies.
The document discusses guidelines from the International Conference on Harmonization (ICH) related to quality and specifications of pharmaceutical products. It describes several ICH Q guidelines including Q1 on stability testing, Q2 on analytical method validation, Q3 on impurities, Q4 on pharmacopoeial harmonization, and Q5 on biotechnological/biological products. Key points covered include requirements for stability testing protocols, validation of analytical methods, identification and qualification of impurities, harmonization of pharmacopoeial standards, and viral safety evaluation of cell-derived biopharmaceuticals.
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSBhaumik Bavishi
The document provides guidelines for submitting stability data for drug substances and drug products as part of a registration application. It outlines the objectives, scope, and general principles of stability testing. Guidelines are given for conducting long-term, accelerated, and intermediate stability studies under various storage conditions. Specifications, testing frequency, number of batches, and container closure systems are also addressed. A commitment to continuing stability studies is recommended if the available data does not cover the proposed shelf life period.
The document discusses guidelines for stability testing from the International Conference on Harmonisation (ICH). It provides an overview of several ICH guidelines related to stability testing of drug substances and products, including guidelines on photostability testing, new dosage forms, bracketing and matrixing designs, and evaluation of stability data. It also summarizes key aspects of conducting stability studies such as selecting representative batches, appropriate container closure systems, testing frequency and storage conditions, and evaluation of results. Stress testing is discussed as a way to validate analytical methods and identify potential degradants.
The document discusses the Common Technical Document (CTD) and electronic Common Technical Document (eCTD), which are standardized formats for submitting documentation to regulatory authorities for approval of new pharmaceutical drugs. The CTD/eCTD are organized into five modules: Module 1 contains administrative information specific to each region; Modules 2-5 are common across regions, with Module 2 summarizing quality, non-clinical and clinical information, Module 3 covering quality aspects, Module 4 containing non-clinical study reports, and Module 5 detailing clinical study reports. The goal of the eCTD is to facilitate the electronic transfer of drug applications and reviews between the pharmaceutical industry and regulatory authorities.
This document discusses the scale-up considerations for producing parenteral drugs on a pilot plant scale. It describes the key unit operations in parenteral production as mixing, sterilization, filtration, filling and sealing. For each unit operation, parameters that must be considered for scale-up are identified, such as tank size and type, impeller design, membrane size, filling rate and container size. Maintaining sterility and avoiding issues like precipitation or clogging are important challenges addressed during scale-up. Quality control tests are used to evaluate the scaled processes. Proper scale-up allows efficient transition from laboratory to commercial production of injectable drug products.
The document provides an overview of stability testing during product development. It discusses the importance of stability testing to ensure product quality and safety over the shelf life. Various methods of stability testing are described, including real-time, accelerated, and retained sample testing. Guidelines for stability testing from ICH, WHO, and other agencies are also covered. The document outlines the key aspects of a stability testing protocol, including batches, containers, storage conditions, sampling plan, test parameters, and acceptance criteria. It provides details on conducting, recording, and presenting stability testing data.
The document discusses the Common Technical Document (CTD) format, which was created by the International Conference on Harmonisation to standardize the submission of documentation for drug approval across regions. It provides a five-module structure for organizing quality, safety, efficacy and other information. While CTD helped streamline submissions, the electronic CTD (eCTD) was later developed to further facilitate electronic transfer and review of documentation between regulators and industry. eCTD utilizes XML formatting and allows lifecycle management of submissions but implementation presents challenges around file formats, regional rules and last minute changes.
stability The ability of a pharmaceutical product to retain its chemical, physical, microbiological and biopharmaceutical properties within specified limits throughout its shelf-life.Why is stability of a drug important?
Drug stability affects the safety and efficacy of the drug product; degradation impurities may cause a loss of efficacy and generate possible adverse effects. Therefore, achieving the chemical and physical stability of drugs is essential to ensure their quality and safety.Common factors that affect this stability include temperature, light, pH, oxidation and enzymatic degradation. Special considerations are also required when dealing with chiral molecules, deuterated internal standards and large biomolecules.
This document discusses stability studies for active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs). It covers topics like applicable guidelines, definitions, stability protocols and reports, stability testing of APIs and FPPs, evaluation of results, and conclusions. Key points include the types of batches tested in stability studies, parameters analyzed, acceptance criteria for significant changes, and guidelines for evaluating stability study results to determine a retest period or shelf life.
Stability study of Pharmaceutical Products and Regulatory Requirements Md. Zakaria Faruki
A marketed product stability program fulfills registration
commitments and ensures that marketed product is
stable until expiry date stamped on product
label....
Stability studies should be planned on the
basis of pharmaceutical R&D and regulatory
requirements...
The document describes the five modules of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Common Technical Document (CTD) format for ASEAN countries. Module 1 contains regional administrative information. Module 2 provides an overall summary of Modules 3, 4, and 5, including quality, non-clinical, and clinical overviews. Module 3 includes chemistry, manufacturing, and quality control documents. Module 4 contains non-clinical safety data. Module 5 provides clinical study reports, though generics only need to include bioequivalence studies. The CTD format is required for both new drug and generic applications in ASEAN countries.
This document discusses guidelines from the International Council for Harmonisation (ICH) for stability testing of drug substances and products. It provides guidance on topics such as the need for harmonized stability testing, types of stability testing, selection of batches and storage conditions for testing, and evaluation of stability data. The guidelines aim to establish a systematic approach to stability testing to ensure quality, safety and efficacy over a product's shelf life and recommend conditions for testing drug substances intended for various storage conditions.
This guideline is a revised of the ICHQ1A –stability data package for new drug substance /DRUG PRODUCT .The [urpose of guideline to define stability data package that sufficient for a registration application within the 3 regions of EU ,JAPAN & USA & to maintain the quality of drug products, in relation to safety , efficacy & acceptability throughout the propose shelf life.
The document discusses ICH stability testing guidelines for drug substances and products, outlining the types of studies required including long term, intermediate, and accelerated studies under various storage conditions. Key aspects that are evaluated include physical, chemical, and microbial changes that may occur over time and factors that influence stability such as temperature, humidity, and light exposure. The purpose of stability testing is to establish a product's shelf life and ensure it remains safe and effective when stored as recommended.
This document discusses drug stability and stability testing. It defines stability as the extent to which a product retains its properties over time. Stability testing is necessary to determine shelf life, recommended storage conditions, and ensure safety. There are various types of stability including chemical, physical, and microbiological. Testing is conducted for different formulations like tablets, capsules, emulsions, and involves evaluating attributes like appearance, assay, degradation products, and more. Guidelines provided by ICH help harmonize stability testing globally.
This document provides an overview of Six Sigma, including:
1) A brief history of Six Sigma and how it was developed at Motorola in 1987 to reduce defects by reducing process variation.
2) The two main Six Sigma project methodologies - DMAIC for improving existing processes and DMADV for creating new designs - which both follow five phases inspired by the PDCA cycle.
3) Key Six Sigma concepts like the 1.5 sigma shift, which accounts for long-term increases in process variation, and how this allows Six Sigma to be defined as a process with 3.4 defects per million opportunities.
This document provides an overview of the ICH Q1A(R2) guideline for stability testing of new drug substances and products. The guideline defines the stability data package required for drug registration in major regions. It addresses testing timelines and conditions for long term, intermediate, and accelerated studies on at least three batches of drug substance and product. The goal is to establish a re-test period or shelf life and recommended storage conditions. Specifications must cover attributes susceptible to change that could impact quality, safety or efficacy. The guideline provides detailed recommendations for testing frequency, storage conditions, and evaluation of results.
This document summarizes the ICH guideline for stability testing. The ICH provides guidance on stability testing to ensure drug quality over time under various environmental conditions. Key aspects covered include the objectives of stability testing, variables that affect stability, terminology, and ICH guidelines Q1A through Q1F which provide detailed recommendations on stability testing procedures, data evaluation, and submissions for registration.
This document defines stability testing requirements for new drug products. It outlines that three primary batches packaged in the proposed marketing container closure system should undergo long term testing at 25°C/60% RH or 30°C/65% RH, accelerated testing at 40°C/75% RH, and intermediate testing if needed. Specifications, frequency of testing, storage conditions and a post-approval stability commitment are also addressed. The purpose is to provide evidence of a drug product's quality over time under various environmental conditions and establish a shelf life.
This document discusses 21 CFR Parts 210 and 211, which outline current good manufacturing practices (cGMP) for pharmaceutical manufacturing as established by the U.S. Food and Drug Administration. It provides an overview of the various parts and subparts that comprise the cGMP regulations. These include general provisions, organization and personnel requirements, facilities and equipment specifications, production and process controls, packaging and labeling controls, and quality control. Definitions for key terms covered in the regulations are also presented, such as drug product, active pharmaceutical ingredient, batch, lot number, and theoretical and actual yields.
The document discusses Chemistry, Manufacturing and Controls (CMC) and its role in pharmaceutical product development and regulatory approval. It provides details on:
- The key functions of CMC including process development, facility inspections, and ensuring compliance.
- CMC content requirements for different application types like NDAs, ANDAs, and INDs.
- How the CMC section evolves over clinical trial phases from laboratory to commercial scale.
- Procedures for developing and submitting post-approval study protocols to regulatory agencies.
The document discusses guidelines from the International Conference on Harmonization (ICH) related to quality and specifications of pharmaceutical products. It describes several ICH Q guidelines including Q1 on stability testing, Q2 on analytical method validation, Q3 on impurities, Q4 on pharmacopoeial harmonization, and Q5 on biotechnological/biological products. Key points covered include requirements for stability testing protocols, validation of analytical methods, identification and qualification of impurities, harmonization of pharmacopoeial standards, and viral safety evaluation of cell-derived biopharmaceuticals.
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSBhaumik Bavishi
The document provides guidelines for submitting stability data for drug substances and drug products as part of a registration application. It outlines the objectives, scope, and general principles of stability testing. Guidelines are given for conducting long-term, accelerated, and intermediate stability studies under various storage conditions. Specifications, testing frequency, number of batches, and container closure systems are also addressed. A commitment to continuing stability studies is recommended if the available data does not cover the proposed shelf life period.
The document discusses guidelines for stability testing from the International Conference on Harmonisation (ICH). It provides an overview of several ICH guidelines related to stability testing of drug substances and products, including guidelines on photostability testing, new dosage forms, bracketing and matrixing designs, and evaluation of stability data. It also summarizes key aspects of conducting stability studies such as selecting representative batches, appropriate container closure systems, testing frequency and storage conditions, and evaluation of results. Stress testing is discussed as a way to validate analytical methods and identify potential degradants.
The document discusses the Common Technical Document (CTD) and electronic Common Technical Document (eCTD), which are standardized formats for submitting documentation to regulatory authorities for approval of new pharmaceutical drugs. The CTD/eCTD are organized into five modules: Module 1 contains administrative information specific to each region; Modules 2-5 are common across regions, with Module 2 summarizing quality, non-clinical and clinical information, Module 3 covering quality aspects, Module 4 containing non-clinical study reports, and Module 5 detailing clinical study reports. The goal of the eCTD is to facilitate the electronic transfer of drug applications and reviews between the pharmaceutical industry and regulatory authorities.
This document discusses the scale-up considerations for producing parenteral drugs on a pilot plant scale. It describes the key unit operations in parenteral production as mixing, sterilization, filtration, filling and sealing. For each unit operation, parameters that must be considered for scale-up are identified, such as tank size and type, impeller design, membrane size, filling rate and container size. Maintaining sterility and avoiding issues like precipitation or clogging are important challenges addressed during scale-up. Quality control tests are used to evaluate the scaled processes. Proper scale-up allows efficient transition from laboratory to commercial production of injectable drug products.
The document provides an overview of stability testing during product development. It discusses the importance of stability testing to ensure product quality and safety over the shelf life. Various methods of stability testing are described, including real-time, accelerated, and retained sample testing. Guidelines for stability testing from ICH, WHO, and other agencies are also covered. The document outlines the key aspects of a stability testing protocol, including batches, containers, storage conditions, sampling plan, test parameters, and acceptance criteria. It provides details on conducting, recording, and presenting stability testing data.
The document discusses the Common Technical Document (CTD) format, which was created by the International Conference on Harmonisation to standardize the submission of documentation for drug approval across regions. It provides a five-module structure for organizing quality, safety, efficacy and other information. While CTD helped streamline submissions, the electronic CTD (eCTD) was later developed to further facilitate electronic transfer and review of documentation between regulators and industry. eCTD utilizes XML formatting and allows lifecycle management of submissions but implementation presents challenges around file formats, regional rules and last minute changes.
stability The ability of a pharmaceutical product to retain its chemical, physical, microbiological and biopharmaceutical properties within specified limits throughout its shelf-life.Why is stability of a drug important?
Drug stability affects the safety and efficacy of the drug product; degradation impurities may cause a loss of efficacy and generate possible adverse effects. Therefore, achieving the chemical and physical stability of drugs is essential to ensure their quality and safety.Common factors that affect this stability include temperature, light, pH, oxidation and enzymatic degradation. Special considerations are also required when dealing with chiral molecules, deuterated internal standards and large biomolecules.
This document discusses stability studies for active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs). It covers topics like applicable guidelines, definitions, stability protocols and reports, stability testing of APIs and FPPs, evaluation of results, and conclusions. Key points include the types of batches tested in stability studies, parameters analyzed, acceptance criteria for significant changes, and guidelines for evaluating stability study results to determine a retest period or shelf life.
Stability testing is conducted to provide evidence on how the quality of a drug substance or product varies over time under the influence of environmental factors like temperature and humidity. It helps establish a re-test period or shelf life and recommended storage conditions. Stress testing involves subjecting samples to more extreme conditions to identify potential degradants and validate stability-indicating methods. Protocols specify batches tested, storage conditions, tests conducted, and timepoints. ICH guidelines provide recommendations for stability testing conditions and acceptance criteria.
FDA container closure system & drug stability saurav anand 23 iiphncsaurav
The document provides guidelines on container closure systems for packaging drugs and their stability according to FDA regulations. It defines packaging components and discusses CGMP, CPSC, and USP requirements. The guidelines specify information to submit to the FDA regarding packaging qualification, drug dosage forms, and extraction studies. It also addresses post-approval packaging changes, drug master files, bulk containers, and factors that influence drug stability as per ICH guidelines.
Pharmaceutical development report (pdr)Atul Bhombe
The document discusses the key sections and guidelines for an effective Pharmaceutical Development Report (PDR) as outlined in ICH Q8 and Q8(R1). The six critical sections of a PDR are: 1) active and inactive ingredients, 2) formulation development and properties, 3) manufacturing process development, 4) container closure system, 5) microbiological attributes, and 6) compatibility with diluents. The PDR provides a comprehensive understanding of the product and manufacturing process for regulatory review and should be updated throughout the product lifecycle.
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTSPallavi Christeen
this presentation describes briefly about Bioavailability and Bioequivalence requirements as per US FDA Code of Federal Regulations under title 21 and chapter 320
Handling of Reserve Samples Dr.A. AmsavelDr. Amsavel A
This document provides guidelines for reserve/retention samples of active pharmaceutical ingredients (APIs) and drug products according to various regulations. It discusses:
- Requirements for reserve samples under 21 CFR 211.170 including quantity, packaging, and retention period.
- ICH Q7 guidance on reserve/retention samples including storing samples in the same or better packaging than marketed.
- Details on developing standard operating procedures for handling, packing, labeling, storing, examining, and destroying reserve/retention samples according to cGMP regulations.
- Responses to common questions about reserve/retention sample requirements.
This document outlines an agenda for a training workshop on pharmaceutical development with a focus on paediatric formulations being held from October 15-19, 2007 in Tallinn, Estonia. The workshop will cover various topics including pre-formulation analytical studies, stress testing APIs, the impact of impurities on API specifications, excipient compatibility studies, degradation pathways, and the role of API processing in product instability. The goal is to discuss how preformulation studies influence key decisions in API and drug product development and support establishing appropriate container closure systems and analytical methods.
The document discusses issues with the Drug Regulatory Authority of Pakistan's (DRAP) recommendations for batch sizes in product development and stability studies, which contradict international regulatory science norms. Specifically, DRAP recommends a batch size of only 2,500 tablets for lab-scale trials and stability testing every 1-2 weeks, rather than the accepted standards of at least 25% of pilot-scale batch size and testing every 3-6 months. The author argues this approach is not supported by any scientific reference and could compromise drug quality, safety and efficacy. The document advocates for DRAP to align its practices with international guidelines from organizations like the International Council for Harmonization to strengthen regulatory systems in Pakistan and better serve patients and industry.
The document discusses bioequivalence studies, which are used to demonstrate that a generic drug is therapeutically equivalent to the branded reference drug by having the same rate and extent of absorption. Such studies assess the in vivo performance of drug products by measuring pharmacokinetic parameters like AUC, Cmax, and Tmax in biological fluids. Proper study design, including fasting versus fed states and multiple dosing, is important to accurately evaluate bioequivalence.
This document outlines an agenda for a training workshop on pharmaceutical development with a focus on paediatric formulations being held from October 15-19, 2007 in Tallinn, Estonia. The workshop will cover various topics including pre-formulation analytical studies, stress testing APIs, the impact of impurities on API specifications, excipient compatibility studies, degradation pathways like hydrolysis and oxidation, and the role of preformulation in selecting appropriate drug products and manufacturing processes. One of the presentations will focus on pre-formulation analytical studies and their impact on API and formulation development.
This document provides a summary of guidelines for stability testing of biotechnological/biological products. It discusses the need for stringent stability testing programs for these products given their sensitivity to environmental factors. It recommends testing the drug substance and drug product from at least 3 batches that represent the manufacturing scale. A minimum of 6 months of real-time, real-condition stability data should be submitted initially to support the requested storage period. The quality of batches in the stability program should match what was used in clinical studies. Ongoing updates of stability data may be needed during regulatory review.
This document discusses blend uniformity analysis (BUA), which tests the adequacy of mixing active pharmaceutical ingredients with other drug product components. BUA is recommended for dosage forms requiring content uniformity testing. Under good manufacturing practices, each commercial batch must be tested to validate uniform mixing. Sample size for BUA is typically 6-10 points, with samples less than 3 times an individual dose. Acceptance criteria for BUA assays is 90-110% of the mean with an RSD of no more than 5%. Stratified sampling targets locations with higher failure risks. The Product Quality Research Institute recommends additionally testing stratified dosage unit samples throughout production.
Generic drugs can be approved through an Abbreviated New Drug Application (ANDA) which relies on the safety and efficacy data of the branded drug. The ANDA process requires generic manufacturers to show bioequivalence to the branded drug through bioavailability and bioequivalence studies rather than completing full clinical trials. If bioequivalence is established, it demonstrates that the generic drug delivers the same amount of active ingredients into a patient's bloodstream in the same amount of time as the branded drug. The Hatch-Waxman Act established the modern ANDA approval process and aims to balance promoting generic drugs to reduce costs while also compensating branded manufacturers for regulatory time lost from patents.
This document summarizes guidelines for stability testing of biotechnological and biological products. It discusses factors that can affect stability, including temperature, humidity, light and container materials. The guidelines specify conducting real-time stability studies at the proposed storage temperature and testing potency, purity and degradation over time. Manufacturers must propose a stability-indicating profile and validate methods to detect any changes to the identity, purity or potency of the product.
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...Neo4j
Leonard Jayamohan, Partner & Generative AI Lead, Deloitte
This keynote will reveal how Deloitte leverages Neo4j’s graph power for groundbreaking digital twin solutions, achieving a staggering 100x performance boost. Discover the essential role knowledge graphs play in successful generative AI implementations. Plus, get an exclusive look at an innovative Neo4j + Generative AI solution Deloitte is developing in-house.
Threats to mobile devices are more prevalent and increasing in scope and complexity. Users of mobile devices desire to take full advantage of the features
available on those devices, but many of the features provide convenience and capability but sacrifice security. This best practices guide outlines steps the users can take to better protect personal devices and information.
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024Neo4j
Neha Bajwa, Vice President of Product Marketing, Neo4j
Join us as we explore breakthrough innovations enabled by interconnected data and AI. Discover firsthand how organizations use relationships in data to uncover contextual insights and solve our most pressing challenges – from optimizing supply chains, detecting fraud, and improving customer experiences to accelerating drug discoveries.
“An Outlook of the Ongoing and Future Relationship between Blockchain Technologies and Process-aware Information Systems.” Invited talk at the joint workshop on Blockchain for Information Systems (BC4IS) and Blockchain for Trusted Data Sharing (B4TDS), co-located with with the 36th International Conference on Advanced Information Systems Engineering (CAiSE), 3 June 2024, Limassol, Cyprus.
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdfMalak Abu Hammad
Discover how MongoDB Atlas and vector search technology can revolutionize your application's search capabilities. This comprehensive presentation covers:
* What is Vector Search?
* Importance and benefits of vector search
* Practical use cases across various industries
* Step-by-step implementation guide
* Live demos with code snippets
* Enhancing LLM capabilities with vector search
* Best practices and optimization strategies
Perfect for developers, AI enthusiasts, and tech leaders. Learn how to leverage MongoDB Atlas to deliver highly relevant, context-aware search results, transforming your data retrieval process. Stay ahead in tech innovation and maximize the potential of your applications.
#MongoDB #VectorSearch #AI #SemanticSearch #TechInnovation #DataScience #LLM #MachineLearning #SearchTechnology
AI 101: An Introduction to the Basics and Impact of Artificial IntelligenceIndexBug
Imagine a world where machines not only perform tasks but also learn, adapt, and make decisions. This is the promise of Artificial Intelligence (AI), a technology that's not just enhancing our lives but revolutionizing entire industries.
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?Speck&Tech
ABSTRACT: A prima vista, un mattoncino Lego e la backdoor XZ potrebbero avere in comune il fatto di essere entrambi blocchi di costruzione, o dipendenze di progetti creativi e software. La realtà è che un mattoncino Lego e il caso della backdoor XZ hanno molto di più di tutto ciò in comune.
Partecipate alla presentazione per immergervi in una storia di interoperabilità, standard e formati aperti, per poi discutere del ruolo importante che i contributori hanno in una comunità open source sostenibile.
BIO: Sostenitrice del software libero e dei formati standard e aperti. È stata un membro attivo dei progetti Fedora e openSUSE e ha co-fondato l'Associazione LibreItalia dove è stata coinvolta in diversi eventi, migrazioni e formazione relativi a LibreOffice. In precedenza ha lavorato a migrazioni e corsi di formazione su LibreOffice per diverse amministrazioni pubbliche e privati. Da gennaio 2020 lavora in SUSE come Software Release Engineer per Uyuni e SUSE Manager e quando non segue la sua passione per i computer e per Geeko coltiva la sua curiosità per l'astronomia (da cui deriva il suo nickname deneb_alpha).
Programming Foundation Models with DSPy - Meetup SlidesZilliz
Prompting language models is hard, while programming language models is easy. In this talk, I will discuss the state-of-the-art framework DSPy for programming foundation models with its powerful optimizers and runtime constraint system.
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
Dr. Sean Tan, Head of Data Science, Changi Airport Group
Discover how Changi Airport Group (CAG) leverages graph technologies and generative AI to revolutionize their search capabilities. This session delves into the unique search needs of CAG’s diverse passengers and customers, showcasing how graph data structures enhance the accuracy and relevance of AI-generated search results, mitigating the risk of “hallucinations” and improving the overall customer journey.
HCL Notes and Domino License Cost Reduction in the World of DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-and-domino-license-cost-reduction-in-the-world-of-dlau/
The introduction of DLAU and the CCB & CCX licensing model caused quite a stir in the HCL community. As a Notes and Domino customer, you may have faced challenges with unexpected user counts and license costs. You probably have questions on how this new licensing approach works and how to benefit from it. Most importantly, you likely have budget constraints and want to save money where possible. Don’t worry, we can help with all of this!
We’ll show you how to fix common misconfigurations that cause higher-than-expected user counts, and how to identify accounts which you can deactivate to save money. There are also frequent patterns that can cause unnecessary cost, like using a person document instead of a mail-in for shared mailboxes. We’ll provide examples and solutions for those as well. And naturally we’ll explain the new licensing model.
Join HCL Ambassador Marc Thomas in this webinar with a special guest appearance from Franz Walder. It will give you the tools and know-how to stay on top of what is going on with Domino licensing. You will be able lower your cost through an optimized configuration and keep it low going forward.
These topics will be covered
- Reducing license cost by finding and fixing misconfigurations and superfluous accounts
- How do CCB and CCX licenses really work?
- Understanding the DLAU tool and how to best utilize it
- Tips for common problem areas, like team mailboxes, functional/test users, etc
- Practical examples and best practices to implement right away
Infrastructure Challenges in Scaling RAG with Custom AI modelsZilliz
Building Retrieval-Augmented Generation (RAG) systems with open-source and custom AI models is a complex task. This talk explores the challenges in productionizing RAG systems, including retrieval performance, response synthesis, and evaluation. We’ll discuss how to leverage open-source models like text embeddings, language models, and custom fine-tuned models to enhance RAG performance. Additionally, we’ll cover how BentoML can help orchestrate and scale these AI components efficiently, ensuring seamless deployment and management of RAG systems in the cloud.
UiPath Test Automation using UiPath Test Suite series, part 5DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 5. In this session, we will cover CI/CD with devops.
Topics covered:
CI/CD with in UiPath
End-to-end overview of CI/CD pipeline with Azure devops
Speaker:
Lyndsey Byblow, Test Suite Sales Engineer @ UiPath, Inc.
UiPath Test Automation using UiPath Test Suite series, part 5
Stability studies
1. 2006.01.09. Dr. Pogány - Guilin 1/61
WHO Training Workshop on Pharmaceutical Quality,
GMP and Bioequivalence with a focus on artemisinines
János Pogány, pharmacist, Ph.D.
consultant to WHO
Guilin, China, 9 January 2006
E-mail: pogany@t-online.hu
STABILITY STUDIES
Assessment experience
2. 2006.01.09. Dr. Pogány - Guilin 2/61
Abbreviations
API Active Pharmaceutical Ingredient
EoI Expression of Interest
FDC Fixed-Dose Combination
FPP Finished Pharmaceutical Product
GMP Good Manufacturing Practices
ICH International Conference on Harmonization
MA Marketing Authorization
DRA Drug Regulatory Authority
Yellow → emphasis Green → WHO Blue → ICH
3. 2006.01.09. Dr. Pogány - Guilin 3/61
Applicable guidelines
WHO „Guidelines for stability testing of
pharmaceutical products containing well
established drug substances in conventional
dosage forms”
WHO working document QAS/05.146 - Stability
Studies in a Global Environment.
ICH guidelines Q1A-Q1F. Stability testing of new
APIs and FPPs has been harmonized at global
level.
4. 2006.01.09. Dr. Pogány - Guilin 4/61
Applicable guidelines
WHO „Guideline on Submission of Documentation
for Prequalification of Multi-source (Generic)
Finished Pharmaceutical Products (FPPs) Used in
the Treatment of HIV/AIDS, Malaria and
Tuberculosis. Annex 4. Stability requirements for
variations and changes to prequalified FPPs (draft)
Supplement 2 [for use from July 2005 (CPH25)]
Extension of the WHO List of Stable (not easily
degradable ARV) APIs. Further potential APIs are
e.g., amodiaquine, mefloquine, and so on.
5. 2006.01.09. Dr. Pogány - Guilin 5/61
Subjects for Discussion
1. Essential ICH definitions
2. Interchangeability of FPPs
3. Planning stability studies and reporting results
4. Stability testing of APIs
5. Stability testing of FPPs
6. Evaluation of stability results
7. Main points again
7. 2006.01.09. Dr. Pogány - Guilin 7/61
Selected definitions
Re-test date
The date after which samples of an API should be examined to
ensure that the material is still in compliance with the
specification and thus suitable for use in the manufacture of a
given FPP.
Shelf life (expiration dating period, conformance period)
The time period during which an API or a FPP is expected to
remain within the approved shelf-life specification, provided
that it is stored under the conditions defined on the container
label. See also Notes Page
8. 2006.01.09. Dr. Pogány - Guilin 8/61
Selected definitions
Formal stability studies
Long term and accelerated (and intermediate) studies undertaken on
primary and/or commitment batches according to a prescribed stability
protocol to establish or confirm the re-test period of an API or the shelf life
of a FPP.
Stress testing – forced degradation (API)
Studies undertaken to elucidate the intrinsic stability of the API. Such
testing is part of the development strategy and is normally carried out
under more severe conditions than those used for accelerated testing.
Stress testing – forced degradation (FPP)
Studies undertaken to assess the effect of severe conditions on the FPP.
Such studies include photostability testing (see ICH Q1B) and
compatibility testing on APIs with each other in FDCs and API(s) with
excipients during formulation development. See also Notes Page
9. 2006.01.09. Dr. Pogány - Guilin 9/61
Selected definitions
Primary batch
A batch of an API or FPP used in a formal stability study, from
which stability data are submitted in a registration application for the
purpose of establishing a re-test period or shelf life, respectively. A
primary batch of an API should be at least a pilot scale batch. For a
FPP, two of the three batches should be at least pilot scale batch, and
the third batch a production batch.
Commitment batches
Production batches of a drug substance or drug product for which the
stability studies are initiated or completed post approval through a
commitment made in the registration application. See also Notes Page
10. 2006.01.09. Dr. Pogány - Guilin 10/61
Selected definitions
Pilot (scale) batch
A batch of an API or FPP manufactured by a procedure
fully representative of and simulating that to be applied to a
full production scale batch. (For solid oral dosage forms, a pilot
scale is generally, at a minimum, one-tenth that of a full production
scale or 100,000 tablets or capsules, whichever is the larger.)
Production (scale) batch
A batch of an API or FPP manufactured at production scale
by using production equipment in a production facility as
specified in the application.
11. 2006.01.09. Dr. Pogány - Guilin 11/61
Selected definitions
Supporting data
Data, other than those from formal stability studies, that
support the analytical procedures, the proposed re-test
period or shelf life, and the label storage statements. Such
data include (1) stability data on early synthetic route
batches of API, small-scale batches of materials,
investigational formulations not proposed for marketing,
related formulations, and product presented in containers
and closures other than those proposed for marketing; (2)
information regarding test results on containers; and (3)
other scientific rationales.
12. 2006.01.09. Dr. Pogány - Guilin 12/61
Selected definitions
Specification - Release
The combination of physical, chemical, biological, and microbiological
tests and acceptance criteria that determine the suitability of a drug
product at the time of its release.
Specification - Shelf life
The combination of physical, chemical, biological, and microbiological
tests and acceptance criteria that determine the suitability of an API
throughout its re-test period, or that anFPP should meet throughout its
shelf life. See also Notes Page
Mass balance
The process of adding together the assay value and levels of degradation
products to see how closely these add up to 100% of the initial value,
with due consideration of the margin of analytical error.
14. 2006.01.09. Dr. Pogány - Guilin 14/61
Interchangeability (IC)
Interchangeability (IC) of multisource FPPs =
(Essential similarity with innovator FPP) =
Pharmaceutical equivalence (PE) +
Bioequivalence (BE)
IC = PE + BE
15. 2006.01.09. Dr. Pogány - Guilin 15/61
Pharmaceutical equivalence
FPPs meet same or comparable standards
(pharmacopoeia, marketing authorization)
Same API (chemical and physical
equivalence)
Same dosage form and route of administration
Same strength
Comparable labeling
WHO-GMP (batch-to-batch uniformity of quality)
STABILITY EQUIVALENCE
16. 2006.01.09. Dr. Pogány - Guilin 16/61
High-risk APIs and FPPs
Reference standard/comparator is not available for:
Pharmaceutical (stability) equivalence studies
Bioequivalence studies
APIs and FPPs are not official in the internationally used
major pharmacopoeias
WHO guides/SOPs apply to multisource FPPs. ICH
guides should be used for evaluation.
Require particular attention by national DRA as regards
assessment of applications for marketing authorization
17. 2006.01.09. Dr. Pogány - Guilin 17/61
Low-risk APIs
1. Certificate of suitability (DRA)
2. Drug Master File
Open part (APPLICANT)
Closed part (DRA)
3. Pharmacopeia monograph
Literature evidence of stability
Synthesis impurities are controlled by monograph (toxicology of
additional impurities)
Class1 solvents excluded, class2 solvents controlled
4. FPP is registered in the ICH region
19. 2006.01.09. Dr. Pogány - Guilin 19/61
Stability Protocol and Report
1. Batches tested
2. General information
3. Container/closure system
4. Literature and supporting data
5. Stability-indicating analytical methods
6. Testing plan
7. Test parameters
8. Test results
9. Other requirements (post-approval commitments)
10. Conclusions
Result sheets must bear date and responsible person
signature / QA approval
20. 2006.01.09. Dr. Pogány - Guilin 20/61
Illustrative data of API stability batches
The batches should be representative of the manufacturing process and should
be manufactured from different batches of key intermediates.
Batch number
Date of manufacture
Site of manufacture
Batch size (kg)
Primary packing materials
Date of initial analysis
21. 2006.01.09. Dr. Pogány - Guilin 21/61
Illustrative data of capsule/tablet stability batches
Batch number
Date of manufacture
Site of manufacture
Batch size (kg)
Batch size (number of units)
Primary packing materials
Date of initial analysis
Batch number of the API
The batches should be representative of the manufacturing process and should
be manufactured from different batches of APIs.
23. 2006.01.09. Dr. Pogány - Guilin 23/61
ICH guidelines on stress testing
Standard Title and reference
ICH Q1A(R2) Stability Testing of New Drug Substances and
Products (the parent guideline)
ICH Q1B Photostability Testing of New Drug Substances and
Products
ICH Q2B Validation of Analytical Procedures: Methodology
ICH Q3A(R) Impurities in New Drug Substances
ICH Q3B(R) Impurities in New Drug Products
24. 2006.01.09. Dr. Pogány - Guilin 24/61
Forced degradation tests
To identify potential degradants (degradation
pathways) of the API and assess if they can be
formed during manufacture or storage of the FPP
(intrinsic stability of the API).
To validate the stability indicating power of the
analytical procedures.
To identify stability-affecting factors such as ambient
temperature, humidity and light and to select packing
materials, which protect the FPP against such effects.
No standard method for testing. See also Notes Page
25. 2006.01.09. Dr. Pogány - Guilin 25/61
Prequalification experience
Results Comments
Deceptive Degradation level is good (<15%) but no
relevant degradants are observed
Predictive Degradation level is good (<15%) and at
least one or all relevant degradants are
observed
Useless Between 15 and 100% degradation but no
relevant degradants observed
26. 2006.01.09. Dr. Pogány - Guilin 26/61
Requirements for predictive stress conditions
Recommendations in Supplement 2:
Should lead to the degradation of the main
compound, but not more than 5-15%.
Should lead to a good predictability of
degradation pathways (i.e., a low probability of
"drastic" or "false" degradation)
Should be conducted for no longer than three
months.
27. 2006.01.09. Dr. Pogány - Guilin 27/61
Stress testing of API in solution
Storage conditions Testing period*
pH ± 2, room temperature 2 weeks
pH ± 7, room temperature 2 weeks
pH ± 10-12, room temperature 2 weeks
H2
O2
, 0.1-2% at neutral pH, room
temperature
24 hours
* Storage times given or 5-15% degradation, whatever comes first
See also Notes Page
28. 2006.01.09. Dr. Pogány - Guilin 28/61
Regulatory or formal stability testing
Storage temperature
(°C)
Relative
humidity
(%)
Minimum time
period covered by
data at submission
(months)
Accelerated: 40±2 75±5 6
Intermediate: 30±2 65±5 12
Long term: 25±2 60±5 12 (6)
29. 2006.01.09. Dr. Pogány - Guilin 29/61
Stability Room
1. A special cabinet for each
condition
2. Design, construction,
qualification, monitoring
3. Costs of operation including
R + D failures
4. Time
5. Do we need new standard
conditions?
30. 2006.01.09. Dr. Pogány - Guilin 30/61
Stability results
A storage statement should be proposed for the
labeling (if applicable), which should be based on
the stability evaluation of the API.
A re-test period should be derived from the stability
information, and the approved retest date should be
displayed on the container label.
An API is considered as stable if it is within the
defined/regulatory specifications when stored at 30±2o
C and
65±5% RH for 2 years and at 40±2o
C and 75±5%RH for 6
months.
32. 2006.01.09. Dr. Pogány - Guilin 32/61
Potential instability issues of FPPs
Loss/increase in concentration of API
Formation of (toxic) degradation products
Modification of any attribute of functional relevance
Alteration of dissolution time/profile or bioavailability
Decline of microbiological status
Loss of package integrity
Reduction of label quality
Loss of pharmaceutical elegance and patient acceptability
33. 2006.01.09. Dr. Pogány - Guilin 33/61
3.11.1 Stability-indicating quality parameters
Stability studies should include testing of those
attributes of the FPP that are susceptible to change
during storage and are likely to influence quality,
safety and/or efficacy. For instance, in case of
tablets:
♦ appearance ♦ hardness
♦ friability ♦ moisture content
♦ dissolution time ♦ degradants
♦ assay ♦ microbial purity
34. 2006.01.09. Dr. Pogány - Guilin 34/61
Increase in concentration of API
During stability studies of Artesunate, the assay results were
increasing. The hydrolysis may yield artenimol and succinic acid.
The latter can justify the increase in assay. The assay method is
„stability indicating” but not specific.
+
35. 2006.01.09. Dr. Pogány - Guilin 35/61
3.11.3 Selection of Batches
At the time of submission data from stability studies
should be provided for batches of the same formulation
and dosage form in the container closure system proposed
for marketing.
Stability data on three primary batches are to be provided.
The composition, batch size, batch number and
manufacturing date of each of the stability batches should
be documented and the certificate of analysis at batch
release should be attached.
Where possible, batches of the FPP should be
manufactured by using different batches of the API.
36. 2006.01.09. Dr. Pogány - Guilin 36/61
Significant Change of FPPs
A 5% change in assay from its initial value.
Any degradation product exceeding its acceptance
criterion.
Failure to meet the acceptance criteria for
appearance, physical attributes, and functionality
test (e.g., color, phase separation, hardness).
As appropriate for the dosage form, e.g., failure to
meet the acceptance criteria for dissolution for 12
dosage units.
37. 2006.01.09. Dr. Pogány - Guilin 37/61
Pitfall
The assay value is still within the limits but the
change during stability is more than 5.0%
Example
Release assay limit: 95.0 – 105.0%
Stability assay limit: 92.5 – 105.0%
Release assay: 101.0% (within spec)
24-Month assay: 93.0% (within spec)
Loss in potency: 8.0%.
This is a significant change.
38. 2006.01.09. Dr. Pogány - Guilin 38/61
2.2.3 Tests at elevated temperature and/or
extremes of humidity (ICH-Q1F)
Special transportation and climatic conditions outside the storage
conditions recommended in this guideline should be supported by
additional data. For example, these data can be obtained from studies on
one batch of drug product conducted for up to 3 months at 50°C/ambient
humidity to cover extremely hot and dry conditions and at 25°C/80% RH
to cover extremely high humidity conditions.
Stability testing at a high humidity condition, e.g., 25°C/80% RH, is
recommended for solid dosage forms in water-vapour permeable
packaging, e.g., tablets in PVC/aluminum blisters, intended to be
marketed in territories with extremely high humidity conditions in Zone
IV. However, for solid dosage forms in primary containers designed to
provide a barrier to water vapour, e.g. aluminum/aluminum blisters,
stability testing at a storage condition of extremely high humidity is not
considered necessary.
39. 2006.01.09. Dr. Pogány - Guilin 39/61
Stress testing of FPPs in solid state
Storage conditions Testing period*
40°C, 75 % RH; open storage** 3 months
50-60 °C, ambient RH; open
storage
3 months
Photostability; according to ICH according to ICH
* 3 months or 5-15% degradation, whatever comes first
** For API1-API2, or API-excipient, or FPP without packing material,
typically a thin layer of material is spread in a Petri dish. Open storage is
recommended, if possible.
41. 2006.01.09. Dr. Pogány - Guilin 41/61
3.11.10 Evaluation
A systematic approach should be adopted in the presentation and
evaluation of the stability information.
Where the data show so little degradation and so little variability
that it is apparent from looking at the data that the requested shelf
life will be granted, it is normally unnecessary to go through the
formal statistical analysis; providing a justification for the omission
should be sufficient.
An approach for analysing data on a quantitative attribute that is
expected to change with time is to determine the time at which the
95% one-sided confidence limit for the mean curve intersects the
(lower) acceptance criterion (95% assay).
42. 2006.01.09. Dr. Pogány - Guilin 42/61
Evaluation – Best Case
1. Tabulate and plot stability data on all attributes
at all storage conditions and evaluate each
attribute separately.
2. No significant change at accelerated conditions
within six (6) months.
3. Long-term data show little or no variability and
little or no change over time.
43. 2006.01.09. Dr. Pogány - Guilin 43/61
Evaluation – Best Case
4. Accelerated data show little or no variability
and little or no change over time.
5. Statistical analysis is normally unnecessary.
6. Proposed retest period or shelf life = double of
period covered by long-tem data (X) but NMT
X + 12 months
7. A retest period or shelf life granted on the basis
of extrapolation should always be verified by
additional long-term stability data
44. 2006.01.09. Dr. Pogány - Guilin 44/61
Visible variability and trend
1. Is there "little or no data
variability"? (High variability without
change over time suggests potential problem
with accuracy/precision of analytical method.)
2. Is there "little or no change-
over-time" in stability data?
45. 2006.01.09. Dr. Pogány - Guilin 45/61
Visible variability and trend
The simple linear regression analysis yields the
equation:
Y = slope X + intercept
where Y is the assay, X is the time factor expressed
in months, the slope is the degradation rate and the
intercept is the assay at time = 0. Regression
analysis provides two additional factors: the p-value
of the slope and the standard deviation about the
regression line SX/Y
46. 2006.01.09. Dr. Pogány - Guilin 46/61
Visible variability and trend
The p-value is the smallest level of significance
that would lead to rejection of the null hypothesis.
(The ICH Q1A states p = 0.25 for accepting the equality
of slopes and zero intercepts of regression lines of
different batches. See Notes page )
Variability is taken to be reflected by the spread
of data around the previously derived regression
line. The standard deviation about the regression
line SY/X
is a measure of this spread.
47. 2006.01.09. Dr. Pogány - Guilin 47/61
Visible variability and trend
To account for the relative nature of the data
variability, it is suggested here to employ the
Capability Index, Cpk, a term borrowed from the field
of statistical process control. The capability of a
process is defined as 6σ, which is the range where
99.7% of the measurements lie (assuming a normal
distribution).
48. 2006.01.09. Dr. Pogány - Guilin 48/61
Process capability index, Cp
acceptance limits UCL - LCL
Cp = =
process capability 6σ*
σ* ... is the measured standard deviation of the process
acceptance limits UCL - LCL
Cpk = =
process capability 6 SY/X
49. 2006.01.09. Dr. Pogány - Guilin 49/61
Visible variability and trend
Perform linear regression analysis on either
accelerated or long-term stability data
p > 0.25. Yes. There is little or no a
change-over-time
Cpk > 2.5. Yes. There is little or no data
variability
51. 2006.01.09. Dr. Pogány - Guilin 51/61
Evaluation – Change with Time
The hypothetical figure in the former slide
illustrates that the extrapolated shelf life is 29
months (25o
C/60%RH) and there is only a 5%
chance that this estimate will be high. Such a plot
covers assay values from 100% down to 95%.
The majority of degradation processes results in
an essentially linear line in this range of the label
claim thus the method is generally applicable for
the estimation of the expiry date at the studied
storage conditions.
53. 2006.01.09. Dr. Pogány - Guilin 53/61
Evaluation – Change with Time*
The hypothetical figure in the former slide illustrates
that the shelf life is 24 months (at a given
temperature). There is a 5% chance that this
estimate will be high. Such a plot covers potency
values from 100% down to 90%.
* DRUG STABILITY — Principles and Practices
Edited by Jens T. Carstensen and C. T. Rhodes
Third edition, revised and expanded (2000)
Marcel Dekker, Inc., 270 Madison Avenue, New York,
55. 2006.01.09. Dr. Pogány - Guilin 55/61
Evaluation – Change with Time
The hypothetical figures in the former slides
illustrate that the shelf life is 31-32 months
(25o
C/60%RH) and there is only a 5% chance that
this estimate will be high. Such a plot covers
degradant values from 0.6% up to 1.4%.
For FPPs in semipermeable containers, loss of
vehicle can result in an increase in the API
concentration. In such cases, the point where the
upper 95% confidence bound intersects the 105%
assay value will define the conformance period.
56. 2006.01.09. Dr. Pogány - Guilin 56/61
Release and shelf-life specifications
It may be appropriate to have justifiable differences
between the shelf life and release acceptance criteria
based on the stability evaluation and the changes
observed on storage.
Shelf-life acceptance criteria should be derived from
consideration of all available stability information.
Release and shelf-life dissolution acceptance criteria
(Q and t) must be the same
List of approved suppliers.
57. 2006.01.09. Dr. Pogány - Guilin 57/61
Commitment
For confirmation of provisional (tentative)
shelf-life, real-time data are required
First 3 production batches on stability
Follow up stability testing (FUST) – one
batch per year
58. 2006.01.09. Dr. Pogány - Guilin 58/61
Additional or New Stability Data
Variations affecting one or more steps of the
same route of synthesis of an API
Change in the route of synthesis of an API
Change in composition of the FPP
Change in immediate packaging of the FPP
59. 2006.01.09. Dr. Pogány - Guilin 59/61
Main points again
Stability studies should be planned on the basis of
pharmaceutical R+D and regulatory requirements.
Forced degradation studies reveal the intrinsic
chemical properties of the API, while formal
stability studies establish the retest date.
The shelf life (expiry date) of FPPs is derived from
formal stability studies.
Variability and time trends of stability data must be
evaluated by the manufacturer in order to propose a
retest date or expiry date.
60. 2006.01.09. Dr. Pogány - Guilin 60/61
Key literature references
Drug Stability: Principles and Practices, 3rd Edition,
edited by Jens T. Carstensen and C. T. Rhodes
(Marcel Dekker, Inc., New York, 2000)
Silke Klick and others: Toward a Generic Approach for
Stress Testing of Drug Substances and Drug Products
(Pharmaceutical Technology, February 2005)
Raphael Bar: Statistical Evaluation of Stability Data:
Criteria for Change-over-time and Data Variability (PDA
Journal of Pharmaceutical Science and Technology, Vol.
57. No.5, Sept./Oct. 2003, pp. 369-377)
Expiration date The date placed on the container label of a n API or FPP designating the time prior to which a batch of the product is expected to remain within the approved shelf life specification if stored under defined conditions, and after which it must not be used. Re-test period The period of time during which the API is expected to remain within its specification and, therefore, can be used in the manufacture of a given FPP , provided that the API has been stored under the defined conditions . After this period, a batch of an API destined for use in the manufacture of a FPP should be re-tested for compliance with the specification and then used immediately. A batch of an API can be re-tested multiple times and a different portion of the batch used after each re-test, as long as it continues to comply with the specification. For most biotechnological/biological substances known to be labile, it is more appropriate to establish a shelf life than a re-test period. The same may be true for certain antibiotics. A re-test period of the API should be derived from the stability information, and a retest date should be displayed on the container label . The long term testing should cover a minimum of 12 months' duration on at least three primary batches at the time of submission and should be continued for a period of time sufficient to cover the proposed shelf life.
Data from formal stability studies should be provided on at least three primary batches of the API . The batches should be manufactured to a minimum of pilot scale by the same synthetic route as, and using a method of manufacture and procedure that simulates the final process to be used for production batches. The overall quality of the batches of API placed on formal stability studies should be representative of the quality of the material to be made on a production scale. The stability studies should be conducted on the API packaged in a container closure system that is the same as or simulates the packaging proposed for storage and distribution. Stability studies should include testing of those attributes of the API that are susceptible to change during storage and are likely to influence quality, safety, and/or efficacy. The long term testing should cover a minimum of 12 months' duration on at least three primary batches at the time of submission and should be continued for a period of time sufficient to cover the proposed re-test period. When available long term stability data on primary batches do not cover the proposed re-test period granted at the time of approval, a commitment should be made to continue the stability studies post approval in order to firmly establish the re-test period . Where the submission includes long term stability data on three production batches covering the proposed re-test period, a post approval commitment is considered unnecessary. Otherwise, one of the following commitments should be made: 1. If the submission includes data from stability studies on at least three production batches, a commitment should be made to continue these studies through the proposed re-test period. 2. If the submission includes data from stability studies on fewer than three production batches , a commitment should be made to continue these studies through the proposed re-test period and to place additional production batches, to a total of at least three, on long term stability studies through the proposed re-test period. 3. I f the submission does not include stability data on production batches, a commitment should be made to place the first three production batches on long term stability studies through the proposed retest date and on accelerated studies for 6 months. 3. The stability protocol used for long term studies for the stability commitment should be the same as that for the primary batches , unless otherwise scientifically justified.
The long term testing of the FPP should cover a minimum of 12 months' duration on at least three primary batches at the time of submission and should be continued for a period of time sufficient to cover the proposed shelf life. Stability testing should be conducted on the dosage form packaged in the container closure system proposed for marketing (including, as appropriate, any secondary packaging and container label). When available long term stability data on primary batches of the FPP do not cover the proposed shelf life granted at the time of prequalification , a commitment should be made to continue the stability studies post approval in order to firmly establish the shelf life . Where the submission includes long term stability data from three production batches covering the proposed shelf life, a post approval commitment is considered unnecessary. Otherwise, one of the following commitments should be made: 1. If the submission includes data from stability studies on at least three production batches, a commitment should be made to continue the long term studies through the proposed shelf life and the accelerated studies for 6 months. 2. If the submission includes data from stability studies on fewer than three production batches, a commitment should be made to continue the long term studies through the proposed retest period and the accelerated studies for 6 months, and to place additional production batches, to a total of at least three, on long term stability studies through the proposed shelf life and on accelerated studies for 6 months. The stability protocol used for long term studies for the stability commitment should be the same as that for the primary batches , unless otherwise scientifically justified.
Shelf life acceptance criteria should be derived from consideration of all available stability information. It may be appropriate to have justifiable differences between the shelf life and release acceptance criteria based on the stability evaluation and the changes observed on storage .
Q1A(R2) STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS 2.1.2 Stress Testing Stress testing of the drug substance can help identify the likely degradation products , which can in turn help establish the degradation pathways and the intrinsic stability of the molecule and validate the stability indicating power of the analytical procedures used. The nature of the stress testing will depend on the individual drug substance and the type of drug product involved. Stress testing is likely to be carried out on a single batch of the drug substance. It should include the effect of temperatures (in 10°C increments (e.g., 50°C, 60°C, etc.) above that for accelerated testing), humidity (e.g., 75% RH or greater) where appropriate, oxidation, and photolysis on the drug substance. The testing should also evaluate the susceptibility of the drug substance to hydrolysis across a wide range of pH values when in solution or suspension . Photostability testing should be an integral part of stress testing . The standard conditions for photostability testing are described in ICH Q1B. Examining degradation products under stress conditions is useful in establishing degradation pathways and developing and validating suitable analytical procedures. However, it may not be necessary to examine specifically for certain degradation products if it has been demonstrated that they are not formed under accelerated or long term storage conditions. Results from these studies will form an integral part of the information provided to regulatory authorities. 2.2.4. Container Closure System Stability testing should be conducted on the dosage form packaged in the container closure system proposed for marketing (including, as appropriate, any secondary packaging and container label). Any available studies carried out on the drug product outside its immediate container or in other packaging materials can form a useful part of the stress testing of the dosage form or can be considered as supporting information, respectively.
Q2B VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY 1.2 Assay and Impurity Test(s) 1.2.2 Impurities are not available If impurity or degradation product standards are unavailable, specificity may be demonstrated by comparing the test results of samples containing impurities or degradation products to a second well-characterized procedure e.g.: pharmacopoeial method or other validated analytical procedure (independent procedure). As appropriate, this should include samples stored under relevant stress conditions: light, heat, humidity, acid/base hydrolysis and oxidation. For the assay, the two results should be compared. For the impurity tests, the impurity profiles should be compared. Peak purity tests may be useful to show that the analyte chromatographic peak is not attributable to more than one component (e.g., diode array, mass spectrometry). Q3B(R) IMPURITIES IN NEW DRUG PRODUCTS 3. ANALYTICAL PROCEDURES The registration application should include documented evidence that the analytical procedures have been validated and are suitable for the detection and quantitation of degradation products (see ICH Q2A and Q2B guidelines on analytical validation). In particular, analytical procedures should be validated to demonstrate specificity for the specified and unspecified degradation products. As appropriate, this validation should include samples stored under relevant stress condition s: light, heat, humidity, acid/base hydrolysis, and oxidation. When an analytical procedure reveals the presence of other peaks in addition to those of the degradation products (e.g., the drug substance, impurities arising from the synthesis of the drug substance, excipients and impurities arising from the excipients), these peaks should be labeled in the chromatograms and their origin(s) discussed in the validation documentation. The quantitation limit for the analytical procedure should be not more than (:~) the reporting threshold. Degradation product levels can be measured by a variety of techniques, including those that compare an analytical response for a degradation product to that of an appropriate reference standard or to the response of the new drug substance itself. Reference standards used in the analytical procedures for control of degradation products should be evaluated and characterised according to their intended uses. The drug substance can be used to estimate the levels of degradation products. In cases where the response factors are not close, this practice can still be used if a correction factor is applied or the degradation products are, in fact, being overestimated. Acceptance criteria and analytical procedures, used to estimate identified or unidentified degradation products, are often based on analytical assumptions (e.g., equivalent detector response). These assumptions should be discussed in the registration application. Differences between the analytical procedures used during development and those proposed for the commercial product should also be discussed.
For many FPPs , especially most solid oral dosage forms, testing the API in solution may be of limited relevance. However, stress testing in solution is generally seen as relevant both for elucidation of degradation pathways and for specificity testing of the analytical method. In special cases, however, testing the API at elevated temperature in solution may be of interest ( e.g. , to predict stability during autoclaving of a solution). Therefore, testing a n API in solution under elevated temperatures should be considered on a case-by-case basis. Routine testing of radical initiators or transition metals such as Fe 3+ and Cu 2+ as initiators or catalysts for oxidative degradation are not generally regarded as relevant, and a case-by-case approach is recommended.
During stress testing, degradation products can be observed that are not formed during accelerated or long-term stability studies. Hence, these degradation products need not always to be examined. Results from submissions in the prequalification project show that the typically applied conditions usually generate a lot of irrelevant degradation products. Chromatograms cannot be evaluated if drastic conditions are applied and many second- and third-generation degradation products are formed An optimal degradation pattern generated during stress testing would show only those degradation products observed at the end of shelf life in formal stability studies and those that might appear if the API or FPP is not handled or packed properly. Chromatograms thus obtained will be representative and not too complicated to evaluate . Routine testing of radical initiators or transition metals such as Fe 3+ and Cu 2+ as initiators or catalysts for oxidative degradation are not generally regarded as relevant, and a case-by-case approach is recommended.
2.1.9. Evaluation An approach for analyzing the data on a quantitative attribute that is expected to change with time is to determine the time at which the 95% one-sided confidence limit for the mean curve intersects the acceptance criterion. If analysis shows that the batch-to-batch variability is small , it is advantageous to combine the data into one overall estimate. This can be done by first applying appropriate statistical tests (e.g., p values for level of significance of rejection of more than 0.25) to the slopes of the regression lines and zero time intercepts for the individual batches. If it is inappropriate to combine data from several batches, the overall re-test period should be based on the minimum time a batch can be expected to remain within acceptance criteria. The nature of any degradation relationship will determine whether the data should be transformed for linear regression analysis. Usually the relationship can be represented by a linear, quadratic, or cubic function on an arithmetic or logarithmic scale. Statistical methods should be employed to test the goodness of fit of the data on all batches and combined batches (where appropriate) to the assumed degradation line or curve. Limited extrapolation of the real time data from the long term storage condition beyond the observed range to extend the re-test period can be undertaken at approval time, if justified. This justification should be based on what is known about the mechanism of degradation, the results of testing under accelerated conditions, the goodness of fit of any mathematical model, batch size, existence of supporting stability data, etc. However, this extrapolation assumes that the same degradation relationship will continue to apply beyond the observed data. Any evaluation should cover not only the assay, but also the levels of degradation products and other appropriate attributes .